Rate-control treatment and mortality in atrial fibrillation

Circulation

Volumn 132, Issue 17, 2015, Pages 1604-1612

  Chao, Tze Fan ^a,f   Liu, Chia Jen ^b,f,g   Tuan, Ta Chuan ^a,f   Chen, Su Jung ^c,f   Wang, Kang Ling ^a,f   Lin, Yenn Jiang ^a,f   Chang, Shih Lin ^a,f   Lo, Li Wei ^a,f   Hu, Yu Feng ^a,f   Chen, Tzeng Ji ^d,f   Chiang, Chern En ^a,e,f   Chen, Shih Ann ^a,f  

^a Division of Cardiology   (Taiwan)

^b Division of Hematology and Oncology   (Taiwan)

^c Division of Infectious Diseases   (Taiwan)

^d Taipei Veterans General Hospital ^*  (Taiwan)

^e TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^f Cardiovascular Research Center   (Taiwan)

^g NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Adrenergic beta antagonists; Atrial fibrillation; Calcium channel blockers; Digoxin; Heart rate

Indexed keywords

ACEBUTOLOL; ALPRENOLOL; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; CARTEOLOL; CARVEDILOL; DIGOXIN; DILTIAZEM; LABETALOL; METOPROLOL; NADOLOL; PINDOLOL; PROPRANOLOL; TIMOLOL; VERAPAMIL; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT;

AGED; ARTICLE; ATRIAL FIBRILLATION; CONTROLLED STUDY; FEMALE; FOLLOW UP; HAZARD RATIO; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRESCRIPTION; PRIORITY JOURNAL; CAUSE OF DEATH; COHORT ANALYSIS; COMORBIDITY; COMPARATIVE STUDY; DEMOGRAPHY; DRUG EFFECTS; DRUG UTILIZATION; EPIDEMIOLOGY; INCOME; MIDDLE AGED; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PROPORTIONAL HAZARDS MODEL; RISK REDUCTION; TAIWAN; VERY ELDERLY;

ADRENERGIC BETA-ANTAGONISTS; AGED; AGED, 80 AND OVER; ANTI-ARRHYTHMIA AGENTS; ANTICOAGULANTS; ATRIAL FIBRILLATION; CALCIUM CHANNEL BLOCKERS; CAUSE OF DEATH; COHORT STUDIES; COMORBIDITY; CONFOUNDING FACTORS (EPIDEMIOLOGY); DIGOXIN; DRUG UTILIZATION; FEMALE; HEART RATE; HUMANS; INCOME; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PROPORTIONAL HAZARDS MODELS; RESIDENCE CHARACTERISTICS; RISK REDUCTION BEHAVIOR; TAIWAN;

EID: 84946472891     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.114.013709     Document Type: Article

References (24)

1. Chugh SS, Blackshear JL, Shen WK, Hammill SC, Gersh BJ. Epidemiology and natural history of atrial fbrillation: clinical implications. J Am Coll Cardiol. 2001;37:371-378.
2. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, Kellen JC, Greene HL, Mickel MC, Dalquist JE, Corley SD; Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fbrillation. N Engl J Med. 2002;347:1825-1833. doi: 10.1056/NEJMoa021328.
3. Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, Said SA, Darmanata JI, Timmermans AJ, Tijssen JG, Crijns HJ; Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fbrillation. N Engl J Med. 2002;347:1834-1840. doi: 10.1056/NEJMoa021375.
4. Carlsson J, Miketic S, Windeler J, Cuneo A, Haun S, Micus S, Walter S, Tebbe U; STAF Investigators. Randomized trial of rate-control versus rhythm-control in persistent atrial fbrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol. 2003;41:1690-1696. doi:10.1016/S0735-1097(03)00332-2
5. European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alferi O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski P, Rutten FH; ESC Committee for Practice Guidelines. Guidelines for the management of atrial fbrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace. 2010; 12: 1360-1420.
6. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fbrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation. 2014;130:2071-2104.
7. Segal JB, McNamara RL, Miller MR, Kim N, Goodman SN, Powe NR, Robinson K, Yu D, Bass EB. The evidence regarding the drugs used for ventricular rate control. J Fam Pract. 2000;49:47-59.
8. Chen SJ, Liu CJ, Chao TF, Wang KL, Chen TJ, Chou P, Wang FD, Lin SJ, Chiang CE. Dental scaling and atrial fbrillation: a nationwide cohort study. Int J Cardiol. 2013;168:2300-2303. doi: 10.1016/j.ijcard.2013.01.192.
9. Lin LJ, Cheng MH, Lee CH, Wung DC, Cheng CL, Kao Yang YH. Compliance with antithrombotic prescribing guidelines for patients with atrial fbrillation: a nationwide descriptive study in Taiwan. Clin Ther. 2008;30:1726-1736. doi: 10.1016/j.clinthera.2008.09.010.
10. Chang CH, Lee YC, Tsai CT, Chang SN, Chung YH, Lin MS, Lin JW, Lai MS. Continuation of statin therapy and a decreased risk of atrial fbrillation/futter in patients with and without chronic kidney disease. Atherosclerosis. 2014;232:224-230. doi: 10.1016/j.atherosclerosis.2013.11.036.
11. Cheng CL, Kao YH, Lin SJ, Lee CH, Lai ML. Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. Pharmacoepidemiol Drug Saf. 2011;20:236-242. doi: 10.1002/pds.2087.
12. Lin CC, Lai MS, Syu CY, Chang SC, Tseng FY. Accuracy of diabetes diagnosis in health insurance claims data in Taiwan. J Formos Med Assoc. 2005;104:157-163.
13. Perng CL, Shen CC, Hu LY, Yeh CM, Chen MH, Tsai CF, Chiang HL, Hung YP, Su VY, Hu YW, Su TP, Chen PM, Hung JH, Liu CJ, Huang MW. Risk of depressive disorder following non-alcoholic cirrhosis: a nationwide population-based study. PLoS One. 2014;9:e88721. doi: 10.1371/journal.pone.0088721.
14. Steinhoff JP, Sheahan RG. Tachycardia-induced cardiomyopathy: atrial fbrillation and congestive heart failure. Am J Med. Sci. 2005;329:25-28.
15. Fujino T, Yamashita T, Suzuki S, Sugiyma H, Sagara K, Sawada H, Aizawa T, Igarashi M, Yamazaki J. Characteristics of congestive heart failure accompanied by atrial fbrillation with special reference to tachycardia-induced cardiomyopathy. Circ J. 2007;71:936-940. doi: http://doi. org/10.1253/circj.71.936
16. Shinbane JS, Wood MA, Jensen DN, Ellenbogen KA, Fitzpatrick AP, Scheinman MM. Tachycardia-induced cardiomyopathy: a review of animal models and clinical studies. J Am Coll Cardiol. 1997;29:709-715. doi: 10.1016/S0735-1097(96)00592-X.
17. Olshansky B, Rosenfeld LE, Warner AL, Solomon AJ, O'Neill G, Sharma A, Platia E, Feld GK, Akiyama T, Brodsky MA, Greene HL; AFFIRM Investigators. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: approaches to control rate in atrial fbrillation. J Am Coll Cardiol. 2004;43:1201-1208. doi: 10.1016/j. jacc.2003.11.032.
18. Nakamura K, Kusano K, Nakamura Y, Kakishita M, Ohta K, Nagase S, Yamamoto M, Miyaji K, Saito H, Morita H, Emori T, Matsubara H, Toyokuni S, Ohe T. Carvedilol decreases elevated oxidative stress in human failing myocardium. Circulation. 2002;105:2867-2871. doi: 10.1161/01.CIR.0000018605.14470.
19. Wang R, Miura T, Harada N, Kametani R, Shibuya M, Fukagawa Y, Kawamura S, Ikeda Y, Hara M, Matsuzaki M. Pleiotropic effects of the beta-adrenoceptor blocker carvedilol on calcium regulation during oxida-tive stress-induced apoptosis in cardiomyocytes. J Pharmacol Exp Ther. 2006;318:45-52. doi: 10.1124/jpet.105.099903.
20. Lin ZP, Dong M, Liu J. Bisoprolol improved endothelial function and myocardium survival of hypertension with stable angina: a randomized double-blinded trial. Eur Rev Med Pharmacol Sci. 2013;17:794-801.
21. Lu Y, Li L, Zhao X, Huang W, Wen W. Beta blocker metoprolol protects against contractile dysfunction in rats after coronary microembolization by regulating expression of myocardial infammatory cytokines. Life Sci. 2011;88:1009-1015. doi: 10.1016/j.lfs.2011.03.012.
22. Kotecha D, Holmes J, Krum H, Altman DG, Manzano L, Cleland JG, Lip GY, Coats AJ, Andersson B, Kirchhof P, von Lueder TG, Wedel H, Rosano G, Shibata MC, Rigby A, Flather MD; Beta-Blockers in Heart Failure Collaborative Group. Effcacy of β blockers in patients with heart failure plus atrial fbrillation: an individual-patient data meta-analysis. Lancet. 2014;384:2235-2243. doi: 10.1016/S0140-6736(14)61373-8.
23. Lund LH, Benson L, Dahlström U, Edner M, Friberg L. Association between use of β-blockers and outcomes in patients with heart failure and preserved ejection fraction. JAMA. 2014;312:2008-2018. doi: 10.1001/jama.2014.15241.
24. Steinberg BA, Hellkamp AS, Lokhnygina Y, Patel MR, Breithardt G, Hankey GJ, Becker RC, Singer DE, Halperin JL, Hacke W, Nessel CC, Berkowitz SD, Mahaffey KW, Fox KA, Califf RM, Piccini JP; ROCKET-AF Steering Committee and Investigators. Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fbrillation: results from the ROCKET-AF Trial. Eur Heart J. 2015;36:288-296. doi: 10.1093/eurheartj/ehu359.